MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: BioPharmaceuticals _ Biotechnology, Genomics, Genetics, Bioinformatics, Biomanufacturing & Personalized Medicine
*Biotechnology: Key Issues
*Key Terms: Biotechnology
Ligands
Parents
*Key Terms: Biotechnology
BioTechnology
Children
*Ligand essentially passes off the heavy lifting needed to bring drugs to market, enjoying royalties and milestones with relatively little investment costs.
*Ligand has more than 140 partnered programs with over 70 different companies.
*Pioneers: Biotechnology_Ligands
*Trevena is a clinical stage biopharmaceutical company involved in the discovery and development of G-protein coupled receptors biased ligands
$50,000 for Mixed-Ligand Targeting of a Nano-Pharmaceutical Against GBM Stem Cells (2011)
2010: FDA approved the same drug under a different name (Xgeva) for a different use, as the first and only RANK Ligand inhibitor for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors (2010)
Amplimmune's scientific founders from Johns Hopkins University have identified several key immunological ligands and receptors.
Chemically modify microdevices asymmetrically with bioadhesive ligands
Inhibitors of Eph receptor-ligand binding-Burnham Institute for Medical Research
Ligand Pharma_research.investors.com
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
Ligand Targeted Emulsion Technology
Mapping the receptor distribution and ligand binding kinetics on the cell surface:
Peptide Ligands-Arizona State University (AzTE)
Polymeric Microspheres Conjugated with Targeting Ligands for Delivery of Inhibitors Against Microbial and Plant Toxins
Proof of principle that soluble fas ligand can be used to manipulate neutrophil-mediated inflammation.
Receptor-ligand assay for orphan tyrosine kinase receptors-Harvard University Office of Technology Development
Startup focused on ligand-based computation design methods where our seed aims to test its drug discovery engine and pivot them into proprietary drug discovery (vs a service model)
The PINCER™ platform technology transforms antibodies, aptamers and ligands into homogeneous biosensors for the quantification and detection of biomolecules and pathogens.
Trevena, Inc. (NASDAQ: TRVN)